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Purpose: Glucocorticoids are widely used medications. In many pharmacoepidemiological 
studies, duration of individual prescriptions and definition of treatment episodes are important 
issues. However, many data sources lack this information. We aimed to estimate duration of 
individual prescriptions for oral glucocorticoids and to describe continuous treatment episodes 
using the parametric waiting time distribution.
Methods: We used Danish nationwide registries to identify all prescriptions for oral gluco-
corticoids during 1996–2014. We applied the parametric waiting time distribution to estimate 
duration of individual prescriptions each year by estimating the 80th, 90th, 95th and 99th per-
centiles for the interarrival distribution. These corresponded to the time since last prescription 
during which 80%, 90%, 95% and 99% of users presented a new prescription for redemption. 
We used the Kaplan–Meier survival function to estimate length of first continuous treatment 
episodes by assigning estimated prescription duration to each prescription and thereby create 
treatment episodes from overlapping prescriptions.
Results: We identified 5,691,985 prescriptions issued to 854,429 individuals of whom 351,202 
(41%) only redeemed 1 prescription in the whole study period. The 80th percentile for prescrip-
tion duration ranged from 87 to 120 days, the 90th percentile from 116 to 150 days, the 95th 
percentile from 147 to 181 days, and the 99th percentile from 228 to 259 days during 1996–2014. 
Based on the 80th, 90th, 95th and 99th percentiles of prescription duration, the median length 
of continuous treatment was 113, 141, 170 and 243 days, respectively.
Conclusion: Our method and results may provide an important framework for future phar-
macoepidemiological studies. The choice of which percentile of the interarrival distribution 
to apply as prescription duration has an impact on the level of misclassification. Use of the 
80th percentile provides a measure of drug exposure that is specific, while the 99th percentile 
provides a sensitive measure.
Keywords: glucocorticoids, pharmacoepidemiology, prescription duration, parametric waiting 
time distribution
Background
Prescription registries offer huge potential for studying benefits and adverse effects 
of drugs. An important issue in many pharmacoepidemiological studies is timing 
of administration, duration of individual prescriptions, and definition of treatment 
episodes. Many prescription data sources, including the Danish, provide information 
only on the date of prescription redemption together with some information on the 
amount of medication dispensed.1 Thus, it is often necessary to make assumptions 
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about the duration of single prescriptions when conducting 
pharmacoepidemiological research. Information on drug 
exposure must be handled cautiously to achieve meaningful 
results and to avoid false conclusions and it is well known 
that assigning treatment periods in pharmacoepidemiological 
studies is a source of bias.2,3
For some medications, clinical input may be used to guide 
the estimation of duration of individual prescriptions and to 
define treatment episodes. However, there is little consensus 
on how best to do this, and externally defined criteria may 
poorly reflect actual usage patterns.3 Støvring et al recently 
suggested that estimates be based instead on observed usage 
patterns using the parametric waiting time distribution 
(WTD).4 This method allows estimation of the time point at 
which a given proportion of users receiving continued treat-
ment will have redeemed their next prescription, that is, the 
“inter-arrival time”. The method’s primary advantage is in 
assigning duration exposure to prescriptions based only on 
observed prescription redemption patterns.
Glucocorticoids are effective agents for treatment of, 
for example, rheumatic diseases, COPD as well as other 
autoimmune diseases.5 Annual prevalence of systemic glu-
cocorticoid use is up to 3% in the Danish population6 and 
prevalence of long-term oral use (≥3 months) in the UK 
population has been estimated to 1%.7 Importantly, dosing 
regimens, treatment duration, and choice of glucocorticoid 
subtype vary substantially by treatment indication.8
To provide a framework for future pharmacoepidemio-
logical studies on oral glucocorticoids, we aimed to use the 
parametric WTD to estimate duration of individual oral 
glucocorticoid prescriptions and length of continuous treat-
ment episodes.
Methods
Setting
We used Danish national registries. Denmark provides its 
entire population with tax-supported health care, guarantee-
ing cost-free access to health care. A unique central personal 
registration number (the civil registration number) is assigned 
to all Danish residents at birth or upon immigration, enabling 
accurate and unambiguous individual-level linkage of health 
and administrative registries.9
Oral glucocorticoids
Oral glucocorticoids are available only by prescription in 
Denmark. We used the Danish National Prescription Reg-
istry1 to identify all persons in the Danish population who 
redeemed prescriptions for oral glucocorticoids between 
 January 1, 1996 and December 31, 2014. The Danish 
National Prescription Registry records information on the 
customer’s civil registration number, the medication classifi-
cation code (Anatomical Therapeutic Chemical classification 
system of the World Health Organization), date of dispensing, 
the number of packages dispensed, the number of tablets in 
a package, tablet strength, and amount dispensed, expressed 
according to “defined daily doses” (DDDs) developed by 
WHO. A DDD is defined as the assumed average maintenance 
dose per day for a drug used for its main indication in adults.10 
ATC codes for glucocorticoids are provided in Table S1.
Statistical analyses
We first counted the total number of prescriptions redeemed 
for oral glucocorticoids during the study period, and the total 
number of individuals who redeemed these prescriptions. 
We described the cohort according to sex and age at first 
prescription. We tallied the total number of prescriptions 
and total DDDs redeemed for all oral glucocorticoids and 
for individual glucocorticoid substances.
Second, we estimated the duration of individual pre-
scriptions by applying the parametric WTD. This method is 
based on the maximum likelihood estimation of a parametric 
2-component mixture model for the WTD.4 The distribu-
tion component for prevalent users estimates the forward 
recurrence density, which is related to the inter-arrival 
density (distribution of time between subsequent prescrip-
tion redemptions) for users receiving continued treatment. 
The inter-arrival density directly shows the probability of 
the appearance of a new prescription as a function of time. 
We estimated the 80th, 90th, 95th, and 99th percentiles for 
prescription duration (days) for oral glucocorticoid users 
each year from 1996 to 2014. The 80th, 90th, 95th, and 99th 
percentiles of assigned prescription duration in days corre-
sponded to the time within which 80%, 90%, 95% and 99% of 
users, respectively, presented a new prescription. We applied 
the Log-Normal model in estimating the forward recurrence 
density.4 The parametric WTD relies on separation of users 
into 2 categories: prevalent users and incident users. To assess 
whether this method would work, we visually inspected the 
empirical WTD to discern if there was a distinct uniform tail 
toward the end of the observation window and a smoothly 
declining section in the beginning. We stratified subanalyses 
by sex, and age groups (0–19, 20–39, 40–79, ≥80 years of 
age), the number of tablets dispensed, and the amount (DDD) 
dispensed to investigate whether individual prescription 
durations differed according to these variables. The number 
of tablets dispensed was calculated as the number of tablets 
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
22
-M
ar
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Clinical Epidemiology 2017:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
593
Prescription duration and treatment episodes
in a package times the number of packages dispensed and 
categorized as 10–30, 50–60, 100 and ≥200. The amount 
dispensed was calculated as the amount in a package times 
the number of packages dispensed and categorized as ≤25 
DDD, 50–70 DDD, 100–150 DDD and 200–250 DDD.
Third, using each percentile estimated by the parametric 
WTD (80th, 90th, 95th, and 99th), we estimated length of 
first continuous treatment episodes. This was accomplished 
by adding the estimated prescription duration (results from 
the parametric WTD stratified by calendar year) to each 
prescription and then, for each subject, creating treatment 
episodes from overlapping prescriptions (i.e., periods with 
assumed continuous drug treatment). To estimate the length 
of first treatment episodes, we used the Kaplan–Meier sur-
vival function to ascertain the first, fifth, tenth, twenty-fifth, 
fiftieth, seventy-fifth, 90th, 95th and 99th percentiles (treating 
emigration as censoring and death as event).
Fourth, we excluded sporadic prescriptions to obtain a 
cohort of multiple-prescription use. For each prescription, we 
searched for prior or forthcoming prescriptions in the time 
interval defined by the 99th percentile as estimated by the 
WTD. If no prior or forthcoming prescriptions appeared in 
this time interval, we excluded the prescription, as this was 
regarded as a sporadic prescription. We described this cohort 
as we did above for the full cohort.
Statistical analyses were conducted using Stata 14. The 
study was approved by the Danish Data Protection Agency 
(Record number: 2016-051-000001, serial number 448).
Results
During the study period, 5,691,985 prescriptions for oral glu-
cocorticoids (335,161,216 DDDs) were redeemed by 854,429 
individuals (56% female). Median age at first prescription 
redemption was 60 years (Table 1). The number of persons 
who redeemed only 1 prescription during the study period 
was 351,202 (41% of the study population). Prednisolone was 
the most frequent subtype of oral glucocorticoid redeemed 
(4,662,315 prescriptions [82% of total prescriptions] and 
269,275,861 DDDs [80% of total DDDs]) (Table 2). When 
excluding sporadic prescriptions (i.e., multiple-prescription 
use), 4,719,061 prescriptions (275,597,541 DDDs) were 
issued to 418,160 persons (56% female) and median age 
was 66 years (Table 1).
When we applied the parametric WTD, the 80th percen-
tile for prescription duration estimated for each year ranged 
from 87 to 120 days; the 90th percentile ranged from 116 
to 150 days, the 95th percentile from 147 to 181 days, and 
the 99th percentile from 228 to 259 days  (Figure 1). Strati-
fying by sex did not change these estimates substantially 
(Figure 2). When we stratified by age group, the percentiles 
for 2 groups (40–79 years of age and ≥80 years of age) were 
similar to those for overall population (Figure 2). When we 
inspected the empirical WTD for the younger age groups, 
no clear separation of prevalent and incident users appeared. 
Thus, we did not perform analyses separately for these. When 
we stratified by the number of tablets, the 80th percentile 
ranged from 87 to 107 days in the category of 50–60 tablets, 
89–120 for 100 tablets and 121–171 for ≥200 tablets (Figure 
3). When we stratified by the amount, the 80th percentile 
ranged from 90 to 118 days for 50–70 DDD, 120–176 for 
100–150 DDD and 96–132 for 200–250 DDD (Table S2). 
The empirical WTD in the categories of 10–30 tablets and 
≤25 DDD showed no clear separation of prevalent and inci-
dent users. Thus, we did not perform analyses separately for 
these. When restricting to the cohort of multiple-prescription 
use, estimates of the 80th, 90th, 95th, and 99th percentiles of 
prescription duration did not change substantially (Table S3).
When we applied the estimated durations of individual 
prescriptions to the full cohort, length of first treatment epi-
sodes varied depending on selection of percentiles. Applying 
the 80th percentile yielded a median episode length of 113 
days (interquartile range [IQR]: 103–142 days). In contrast, 
applying the 90th, 95th and 99th percentiles yielded median 
episode lengths of 141 days (IQR: 132–184 days), 170 days 
(IQR: 160–224 days), and 243 days (IQR: 232–325 days), 
respectively (Table S4). In the multiple-prescription cohort, 
Table 1 Sex and age distribution among all oral glucocorticoid 
use and multiple-prescription use, Denmark, January 1, 1996 – 
December 31, 2014
Characteristics Number (%)
All use Multiple- 
prescription use
Total number of users 854,429 418,160
Sex
Female 477,633 (56) 235,643 (56)
Male 376,327 (44) 182,369 (44)
Missing 469 (<0.001) 148 (0.04)
Age (years) at first redeemed prescription
Median age 60 66
0–19 30,084 (3.5) 8170 (2.0)
20–39 136,914 (16) 41,992 (10)
40–59 242,769 (28) 97,343 (23)
60–79 334,333 (39) 198,367 (47)
≥80 109,858 (13) 72,140 (17)
Missing 471 (0.06) 148 (0.04)
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the 80th percentile yielded median episode length of 152 
days (IQR: 109–252 days). Applying the 90th, 95th and 99th 
percentiles yielded median episode lengths of 200 days (IQR: 
141–359 days), 248 days (IQR: 173–460 days), and 364 days 
(IQR: 255–691 days), respectively (Table S4).
Discussion
In this nationwide study, we estimated the duration of 
single prescriptions among users of oral glucocorticoids and 
described continuous treatment episodes using the  parametric 
WTD. People who only redeemed 1 prescription in the 
whole study period accounted for 41% of the population. 
Prescription duration ranged from 87 to 299 days depend-
ing on choice of percentile, calendar year as well as number 
of tablets and amount dispensed. Application of the 80th, 
90th, 95th and 99th percentiles yielded median lengths of 
first continuous treatment episodes of 113, 141, 170 and 243 
days, respectively.
This study can provide important information for future 
studies of glucocorticoids. As well, the study provides a 
valuable framework for determining duration of prescribing 
episodes in pharmacoepidemiological studies. Prescription 
Table 2 Number of prescriptions and DDDs redeemed by all oral glucocorticoid use and multiple-prescription use by medication 
subtype, Denmark, January 1, 1996–December 31, 2014
Glucocorticoid 
substance
Number of prescriptions (%) DDD (%)
All use Multiple-prescription use All use Multiple-prescription use
Total 5,691,985 (100) 4,719,061 (100) 335,161,216 (100) 275,597,541 (100)
Betamethasone 1069 (0.02) 872 (0.02) 36,800 (0.01) 30,200 (0.01)
Dexamethasone 6942 (0.12) 2927 (0.06) 115,796 (0.03) 87,380 (0.03)
Methylprednisolone 98,176 (1.7) 70,337 (1.5) 10,875,877 (3.2) 8,235,906 (3.0)
Prednisolone 4,662,315 (82) 3,813,628 (81) 269,275,861 (80) 218,693,311 (79)
Prednisone 786,599 (14) 699,486 (15) 45,159,744 (13) 39,210,258 (14)
Hydrocortisone 136,882 (2.4) 131,811 (2.8) 9,697,138 (3) 9,340,486 (3.4)
Abbreviation: DDDs, defined daily doses.
Figure 1 Estimated 80th, 90th, 95th and 99th percentiles for prescription duration (days) in users of oral glucocorticoids, based on the parametric waiting time distribution.
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registries offer huge potential for studying benefits and 
adverse effects of drugs. However, information on drug 
exposure must be handled cautiously to achieve meaning-
ful results and to avoid false conclusions. It is well known 
that assigning treatment periods in pharmacoepidemiologi-
cal studies is a source of bias.2,3 Decisions about duration 
of single prescriptions and overall length of treatment are 
often not based on evidence. For example, duration of a 
single prescription is often assumed to be 3 months; a grace 
period of, for example, 3 weeks is often added for subsequent 
prescriptions to be considered a part of the same treatment 
episode. Such decisions clearly cause some degree of mis-
classification. Use of the parametric WTD to estimate a 
percentile of the inter-arrival density among continued users 
can be viewed as putting a limit on their misclassification. 
For example, with prescription duration defined on the basis 
of the 95th percentile, only 5% of continuous users will 
mistakenly be classified as having stopped use. When the 
99th percentile is chosen, only 1% of continued users will 
be classified mistakenly as having stopped use. On the other 
hand, use of the 99th percentile is likely to classify a higher 
proportion of individuals as continued users when, in fact, 
Figure 2 Estimated 80th, 90th, 95th and 99th percentiles for prescription duration (days) in users of oral glucocorticoids using the parametric waiting time distribution, 
stratified by sex and age group.
Note: (A) Women, (B) men, (C) age group 40–79 years of age, (D) age group ≥80 years of age.
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Figure 3 Estimated 80th, 90th, 95th and 99th percentiles for prescription duration 
(days) in users of oral glucocorticoids using the parametric waiting time distribution, 
stratified by number of tablets dispensed (number of tablets in a package × number 
of packages dispensed).
Note: (A) 50–60 tablets, (B) 100 tablets, (C) ≥200 tablets.
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they have stopped. In our study, the 80th percentiles were 
87–120 days, whereas the 99th percentiles were 228 to 259 
days. Intermittent users of oral glucocorticoids (e.g., COPD 
patient) may explain the high values of the 99th percentiles. 
The higher percentiles (e.g., the 99th) of the interarrival dis-
tribution are probably not a realistic estimate of prescription 
duration in our population but rather a measure of time since 
last prescription in the group of intermittent users. Notably, 
we found median length of continuous treatment episodes 
close to duration of individual prescriptions, which can be 
explained by the high proportion (41%) of people who only 
redeemed 1 prescription in the whole study.
The method used in this study cannot account for indi-
vidual covariates that might be predictive of the length of 
the interval between 2 consecutive prescriptions. These 
include the number of tablets dispensed, the amount dis-
pensed, frequency of daily intake, the administered dose, 
patient characteristics and any hospitalizations. However, 
we performed stratified analyses by the number of tablets as 
well as amount dispensed. A larger number of tablets yielded 
longer intervals between consecutive prescriptions, whereas 
when stratifying on amount the category of 100–150 DDD 
yielded longer intervals than the category of 200–250 DDD. 
The longer intervals found in the 100–150 DDD category 
compared with the 200–250 DDD category were explained 
by a larger number of tablets dispensed in the 100–150 DDD 
category than in the 200–250 category. For glucocorticoids, 
number of tablets dispensed may be a more logic predictor of 
time interval between consecutive prescriptions than amount 
dispensed. First, amount reflects a mixture of tablet strength 
and number of tablets in a package. Second, DDD does not 
correlate well with prescribed daily dose for glucocorticoids. 
In addition, we stratified by patient characteristics such as 
sex and age group and this did not change the estimates 
appreciably. Other relevant patient characteristics to consider 
could be treatment indication and disease severity; however, 
we were not able to identify these. Furthermore, the WTD 
requires reliable separation of current users into 2 categories: 
prevalent and incident users. Intermittent use may make the 
method less reliable. When there is substantial intermittent 
use, the parametric WTD approach becomes more sensitive to 
choice of parametric distribution, as it is difficult to separate 
the uniform distribution for incidence from a slowly declining 
forward recurrence density for prevalence. We investigated 
this issue by visually inspecting the empirical WTD, to see 
if there was a distinct uniform tail toward the end of the 
observation window and a smoothly declining section in the 
beginning. This was confirmed graphically. In addition, the 
Log-Normal distribution chosen in our analyses is highly 
robust in handling this issue.4
Conclusion 
In conclusion, we estimated the duration of single prescrip-
tions among users of oral glucocorticoids and described 
continuous treatment episodes using the parametric WTD. 
The choice of which percentile of the interarrival density 
to apply as prescription duration has an impact on the level 
of misclassification. Use of the 80th percentile provides a 
measure of drug exposure that is specific, while the 99th 
percentile provides a sensitive measure. In a population 
with intermittent users, as in oral glucocorticoid users, 
the higher percentiles (e.g., the 99th) are probably not 
a realistic estimate of prescription duration but rather a 
measure of time since last prescription in the group of 
intermittent users.
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Table S1 ATC codes for glucocorticoids
Oral glucocorticoids ATC code
Betamethasone H02AB01
Dexamethasone H02AB02
Methylprednisolone H02AB04
Prednisolone H02AB06
Prednisone H02AB07
Hydrocortisone H02AB09
Abbreviation: ATC, Anatomical Therapeutic Classification.
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Table S3 Estimated 80th, 90th, 95th, and 99th percentiles for prescription duration (days) in multiple-prescription use of oral 
glucocorticoids using the parametric waiting time distribution, by calendar year
Calendar year 80th percentile 90th percentile 95th percentile 99th percentile
1996 102 128 154 220
1997 102 130 159 232
1998 98 125 152 222
1999 100 127 156 229
2000 86 114 145 227
2001 99 126 155 226
2002 106 133 161 229
2003 103 131 159 230
2004 102 130 159 232
2005 104 133 162 236
2006 107 136 166 242
2007 107 136 164 236
2008 120 150 181 256
2009 102 132 163 241
2010 105 136 167 246
2011 107 136 165 238
2012 109 139 169 244
2013 110 141 172 251
2014 126 162 200 295
Table S4 Duration (days) of first oral glucocorticoid continous treatment episodes among all use and multiple-prescription use 
estimated by the Kaplan–Meier survival function and presented as 1st, 5th, 10th, 25th, 50th, 75th, 90th, 95th and 99th percentiles
Kaplan–Meier estimated 
percentiles, duration (days)
Parametric WTD estimated percentiles of duration of treatment episodes
80th percentile  90th percentile 95th percentile 99th percentile
All use
1st percentile 9 9 9 9
5th percentile 43 43 43 43
10th percentile 87 116 121 121
25th percentile (Q1) 103 132 160 232
50th percentile (Median) 113 141 170 243
75th percentile (Q3) 142 184 224 325
90th percentile 301 429 544 808
95th percentile 499 777 1029 1593
99th percentile 1298 2149 2999 4545
Multiple-prescription use
1st percentile 28 28 28 28
5th percentile 73 73 73 73
10th percentile 99 124 140 140
25th percentile (Q1) 109 141 173 255
50th percentile (median) 152 200 248 364
75th percentile (Q3) 252 359 460 691
90th percentile 484 783 1058 1664
95th percentile 749 1264 1758 2760
99th percentile 1739 3002 4127 6047
Abbreviation: WTD, waiting time distribution.
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